Table 2.
Summary of logMAR acuity for groups I and II
| Mean (SD) Log MAR Acuity† | |||||
|---|---|---|---|---|---|
|
| |||||
| Visit | N NC, NA |
Injected Eye | Fellow Eye | Difference | |
|
| |||||
| Pre-injection | BL2 | 12 | 1.85 (0.41) | 1.78 (0.37) | 0.08 (0.17) |
| 6, 6 | p*=0.14 | ||||
|
| |||||
| Post-injection follow up | Day 1 | 12 | 1.80 (0.39) | 1.71 (0.33) | 0.09 (0.21) |
| 6, 6 | p=0.16 | ||||
|
| |||||
| Day 7 | 12 | 1.66 (0.34) | 1.69 (0.40) | −0.03 (0.29) | |
| 6, 6 | p=0.72 | ||||
|
| |||||
| Day 30 | 12 | 1.65 (0.36) | 1.70 (0.32) | −0.05 (0.19) | |
| 6, 6 | p=0.37 | ||||
|
| |||||
| Day 60 | 12 | 1.65 (0.35) | 1.69 (0.38) | −0.03 (0.10) | |
| 6, 6 | p=0.27 | ||||
|
| |||||
| Day 90 | 12 | 1.69 (0.38) | 1.69 (0.37) | 0.00 (0.08) | |
| 6, 6 | p=1.00 | ||||
|
| |||||
| Mo 6 | 11 | 1.73 (0.36) | 1.75 (0.34) | −0.03 (0.07) | |
| 6, 5 | p=0.22 | ||||
|
| |||||
| Mo 9 | 8 | 1.67 (0.39) | 1.67 (0.39) | 0.00 (0.08) | |
| 6, 2†† | p=0.87 | ||||
|
| |||||
| Mo 12 | 9 | 1.66 (0.38) | 1.72 (0.38) | −0.06 (0.25) | |
| 6, 3 | p=0.48 | ||||
|
| |||||
| Mo 18 | 7 | 1.47 (0.42) | 1.68 (0.46) | −0.21 (0.25) | |
| 5, 2 | p=0.17 | ||||
|
| |||||
| Mo 24 | 2 | 2.00 (0.00) | 2.00 (0.00) | 0.00 (0.00) | |
| 2, 0 | p=1.00 | ||||
NC = Number of chronic (group I patients), low and medium doses; NA = Number of Acute (group II) patients, low and medium doses; BL2 = baseline 2; Mo = Month
†
Equivalent low vision logMAR acuities: CF = −2.0, HM = −2.3, LP = −2.6
*
2-tailed paired t-test p values assess significance of average difference between injected and fellow eye
††
2-1-08 missed their 9 month study visit but returned for their 12 month visit